Literature DB >> 20528368

Willingness to pay for a QALY: past, present and future.

Helen Mason1, Rachel Baker, Cam Donaldson.   

Abstract

This paper is focused on establishing why a willingness-to-pay per quality-adjusted life-year value is needed and how such a value can be used in healthcare decision-making. Studies that have estimated willingness-to-pay per quality-adjusted life-year values from stated preference data are reviewed and categorized into three groups. These studies are then compared within and between groups highlighting the limitations of existing studies and their suitability for use in policy-making. The future of such work will be discussed, noting key issues for consideration and debate.

Year:  2008        PMID: 20528368     DOI: 10.1586/14737167.8.6.575

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  15 in total

1.  The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.

Authors:  T Younis; D Rayson; C Skedgel
Journal:  Curr Oncol       Date:  2011-12       Impact factor: 3.677

2.  Real economics needs to reflect real decisions: a response to Johnson.

Authors:  Mark Sculpher; Karl Claxton
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

Review 3.  Mobile Stroke Units: Current Evidence and Impact.

Authors:  Praveen Hariharan; Muhammad Bilal Tariq; James C Grotta; Alexandra L Czap
Journal:  Curr Neurol Neurosci Rep       Date:  2022-02-07       Impact factor: 5.081

4.  Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.

Authors:  Christian R C Kouakou; Thomas G Poder
Journal:  Eur J Health Econ       Date:  2021-08-21

5.  Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.

Authors:  N W D Lamond; C Skedgel; D Rayson; T Younis
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

6.  How to assess the value of medicines?

Authors:  Steven Simoens
Journal:  Front Pharmacol       Date:  2010-09-07       Impact factor: 5.810

7.  Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations.

Authors:  Alwin Jeyakumar; Tallal Younis
Journal:  Clin Med Insights Oncol       Date:  2012-04-03

Review 8.  A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?

Authors:  Khachapon Nimdet; Nathorn Chaiyakunapruk; Kittaya Vichansavakul; Surachat Ngorsuraches
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

9.  Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?

Authors:  Montarat Thavorncharoensap; Yot Teerawattananon; Sirin Natanant; Wantanee Kulpeng; Jomkwan Yothasamut; Pitsaphun Werayingyong
Journal:  Clinicoecon Outcomes Res       Date:  2013-01-09

Review 10.  Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.

Authors:  Nathan Wd Lamond; Tallal Younis
Journal:  Int J Womens Health       Date:  2014-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.